General Information
Lilly DM2-Cardiac GPGM
Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
| Protocol | I8F-MC-GPGM |
|---|---|
| Identifier | PO 4900666068 |
| UID | 5f6d5bb1-c5b0-47ac-b73a-44344019f6da |
| Status | Done - Archived |
| Phase | 3 |
| Category | Diabetes Type 2 / Adult |
| Launch Year | 0 |
| NCT Number | - |
| Created | 2018-08-29 12:15 |
| Last Updated | 2018-08-29 12:15 |
Description
No description provided.
Comment
CRI
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | 2019-02-13 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2018-12-06 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2020-02-07 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Miss, Salomon | SMiss | No |
| Coordinator | Rocha, Luis | LRocha | No |
| Regulatory | Perez, Myrna | MPerez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Eli Lilly and Company |
|---|---|
| Division | Lilly |
| Team | Lilly |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | IQVIA RDS Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
